Cel Sci Corporation (CVM)

[mitcheroo]

A bit more readable.

TEDT9 from Yahoo board:

FACT:
Cel-Sci's Multikine therapy was granted Orphan Drug status by the FDA.

FACT:
In the most recent Phase 2 clinical trial, CEL-SCI reported a 10.5% complete response rate (no clinical or pathology evidence of any remaining cancer) and a 33% improvement in overall survival after just three weeks of treatment. NO serious adverse events were reported associated with Multikine.

Rest assured Multikine will exceed the 10% over SOC required.

FACT:
Phase 3 trial lasted over 2 years longer than it was expected to last. This suggests Multikine is working exceptionally well.

FACT:
Normal time from last event to data lock: approximately 21 days. Approximate time from lock to data read [analysis?], 4 to 6 weeks. According to the statisticians I have heard from, there have been cases where data input was loaded in the computer program in 40 to 60 hours.

FACT:
End of the Phase 3 trial (the last event) was confirmed May 4th 2020, which tells you how close we are to the positive top line data release we have been waiting for.


And don't forget that the reconstitution of the Russel 3000 portfolio announced on June 5 should put upward pressure on share price -- not to mention covering 6 MILLION shorted shares.